Is flecainide contraindicated in patients with structural heart disease (e.g., prior myocardial infarction, coronary artery disease, left ventricular systolic dysfunction, heart failure, or significant valvular disease)?

Flecainide is Contraindicated in Structural Heart Disease

Yes, flecainide is absolutely contraindicated in patients with structural heart disease, specifically those with coronary artery disease, prior myocardial infarction, heart failure with reduced ejection fraction (HFrEF), and severe left ventricular hypertrophy. This contraindication is consistently emphasized across current guidelines and FDA labeling, prioritizing patient safety and mortality reduction.

Guideline-Based Contraindications

The 2024 ESC Guidelines provide the most current and explicit recommendations 1:

• Flecainide is recommended ONLY when excluding patients with:
  • Heart failure with reduced ejection fraction (HFrEF)
  • Coronary artery disease
  • Severe left ventricular hypertrophy

This applies to both acute cardioversion and long-term rhythm control strategies. The guidelines specifically state that when these conditions are present, amiodarone should be used instead 1.

The 2016 ACC/AHA/HRS Guidelines reinforce this position, stating that "flecainide and propafenone have a risk of proarrhythmia in patients with structural heart disease or ischemic heart disease and are contraindicated in these patient groups" 2.

FDA Label Warnings

The FDA labeling provides critical safety data 3:

• Heart failure risk: Flecainide has negative inotropic effects and can cause or worsen CHF, particularly in patients with:

  • Cardiomyopathy
  • Preexisting severe heart failure (NYHA class III or IV)
  • Low ejection fractions (<30%)

• Clinical outcomes in structural heart disease:

  • In sustained VT patients: 6.3% developed new CHF
  • In sustained VT patients with existing CHF history: 25.7% developed worsened CHF
  • Exacerbation occurred more commonly in patients with class III or IV heart failure

Specific Structural Heart Disease Categories

Absolute Contraindications:

1. Post-myocardial infarction - Based on CAST trial mortality data
2. HFrEF (EF <40%) - Risk of worsening heart failure and proarrhythmia
3. Active ischemic heart disease - Increased mortality risk
4. Severe LV hypertrophy - Substrate for ventricular arrhythmias

Relative Contraindications Requiring Extreme Caution:

• Cardiomyopathy - Negative inotropic effects problematic
• Significant valvular disease - Depending on hemodynamic impact
• NYHA Class III-IV heart failure - High risk of decompensation

Emerging Evidence and Nuances

Recent observational studies suggest potential safety in highly selected populations 4, 5, 6:

• Stable, nonobstructive CAD without active ischemia may be safer than previously thought 6
• Some cardiomyopathies (arrhythmogenic RV CM, PVC-induced CM) may benefit 4

However, these are observational studies only and do NOT override current guideline recommendations. The 2025 review explicitly states that "randomized controlled trials are needed to confirm the recent observational findings" 4. Until such trials exist, the guideline-based contraindications must be followed.

Clinical Decision Algorithm

Use flecainide ONLY if ALL of the following are true:

1. No history of myocardial infarction
2. No coronary artery disease (or only minimal nonobstructive disease)
3. Normal left ventricular systolic function (EF ≥50%)
4. No severe left ventricular hypertrophy
5. No heart failure (any NYHA class)
6. No significant valvular disease

If ANY structural heart disease is present → Use amiodarone instead 1.

Critical Pitfalls to Avoid

• Do not assume "stable" CAD is safe - Current guidelines make no distinction between stable and unstable CAD for flecainide contraindication 1, 2
• Do not use preserved EF as justification - Even HFpEF with structural abnormalities warrants caution
• Do not rely on observational data - Guidelines and FDA labeling take precedence over emerging observational studies
• Monitor plasma levels if used cautiously - Keep trough levels below 0.7-1.0 mcg/mL 3

The mortality signal from the CAST trial, combined with consistent guideline recommendations and FDA warnings, mandates strict adherence to these contraindications to prevent avoidable deaths and proarrhythmic events.